| Cover and Content | |
| 1-4 |
| New antibiotics approved by EMA and FDA (2020–2024): Trends, access in Bulgaria, and implications for antimicrobial resistance control | |
| Mariya Ilieva | 5-11 |
| How to work safely with hazardous drugs | |
| Velina Grigorova, Evgeni Grigorov | 12-19 |
| Comparative analysis of innovative medicinal products’ marketing authorizations between EMA and FDA with focus on pharmacovigilance | |
| Ines Hababa-Ivanova, Antonio Ivanov, Violeta Getova-Kolarova, Ilko Getov | 20-26 |
| Access to targeted therapy for prostate cancer in Bulgaria | |
| Konstantin Ivanov, Nadia Veleva, Hristina Lebanova | 27-33 |
| Screening program for early detection of breast cancer in Bulgaria | |
| Emilia Krapcheva, Andrean Georgiev, Veneta Todorova, Yoanna Vutova, Margarita Georgieva, Valentina Belcheva, Slaveyko Djambazov, Adriana Dacheva, George Slavchev | 34-42 |
| Pharmacotherapy in patients with acute and exacerbated chronic pyelonephritis | |
| Nedyalko Grigorov, Todor Naydenov, Emine Kalvicheva, Stanislava Barakova | 43-47 |
| Training needs and thematic preferences of hospital pharmacists in Bulgaria: results from the 2025 survey of the Bulgarian Association of Hospital and Clinical Pharmacists (BAHCP) | |
| Mariya lieva, Velina Grigorova, Natalia Kokudeva, Nadezda Grigorova, Tatiana Petrova, Reni Vatkova, Petаr Kavlakov | 48-52 |
| Assisted reproduction and increased risk for mother and child | |
| Ivaneta Yoncheva-Biserova, Hristina Nocheva, Mariana Yoncheva-Mihaylova | 53-61 |
| Development and establishment of the clinical role of the hospital pharmacist in multidisciplinary teams at the European level | |
| Tsvetelina Stefanova, Evgeni Grigorov, Galina Petrova | 62-71 |
| Strategies for the design of drug therapies containing engineered proteins | |
| Toni Vekov, Lidiya Dimova, Valentina Belcheva, Elitza Betcheva-Krajcir | 72-81 |
| New therapeutic approaches in hypertrophic cardiomyopathy | |
| Ralitsa Pancheva, Blagovest Stoimenov | 82-94 |